reports
Endocyte Stockholders Approve Merger Agreement with Novartis AG
Endocyte Stockholders Approve Merger Agreement with Novartis AG WEST LAFAYETTE, Ind., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) (“Endocyte”), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash. Approximately 99.8% of the votes cast at the meeting voted to a...
Endocyte Provides Third Quarter 2018 Financial Results and Operational...
Endocyte Provides Third Quarter 2018 Financial Results and Operational Update Entered into agreement and plan of merger with Novartis AG for $2.1Billion WEST LAFAYETTE, Ind., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the third quarter ended Sept. 30, 2018 and provided an operational update. “177Lu-PSMA-617’s value as a potential treatment for patients with mCRPC has been reinforced in both our regulatory interactio...
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 ...
Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that it has entered into an agreement and plan of merger with Novartis AG (“Novartis”) pursuant to which Novartis will acquire Endocyte for $24 per share, or a total equity value of ap...
Endocyte becomes first Purdue startup to reach $1.5B in value
Endocyte becomes first Purdue startup to reach $1.5B in value Endocyte’s primary cancer drug platforms include “two of the most exciting platforms in all of cancer right now.” One drug shows promising results in treating advanced prostate cancer and the other platform could improve treatment of pediatric bone cancer. West Lafayette, Ind., Oct. 03, 2018 (GLOBE NEWSWIRE) -- (Nasdaq: ECYT), reached a milestone this year when its value recently reached about $1.5 billion and as the company’s drug platforms continue to move through various clinical trials with promising results in treating a...
ENDOCYTE INCO. sees a downgrade to Slightly Negative on account of les...
The independent financial analyst theScreener just lowered the general evaluation of ENDOCYTE INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 2 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 2, 2018, the closing price was USD 17.22 and its targ...
Endocyte to Present at Two Investor Conferences on October 2nd
Endocyte to Present at Two Investor Conferences on October 2nd WEST LAFAYETTE, Ind., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at two upcoming investor conferences in New York, NY, on Tuesday, October 2nd, 2018. Ladenburg Thalmann 2018 Healthcare Conference at 1:30 p.m. EDT.Cantor Fitzgerald Global Healthcare Conference at 4:35 p.m. EDT. Live audio webcasts of the Company’s presentations can be accessed by ...
Endocyte Announces Closing of Public Offering of Common Stock
Endocyte Announces Closing of Public Offering of Common Stock WEST LAFAYETTE, Ind., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of an aggregate of 10,878,379 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase additional shares of common stock, at a price to the public of $18.50 per share. All shares of common stock sold in the offering we...
Endocyte Announces Pricing of Public Offering of Common Stock
Endocyte Announces Pricing of Public Offering of Common Stock WEST LAFAYETTE, Ind., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 9,459,460 shares of its common stock at a price to the public of $18.50 per share. In addition, Endocyte granted the underwriters a 30-day option to purchase up to an additional 1,418,919 shares of its common stock on the same terms and conditions. All share...
Endocyte Announces $175.0 Million Proposed Public Offering of Common S...
Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell $175.0 million of its common stock in an underwritten registered public offering. In addition, Endocyte expects to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of its common stock on the same terms and conditions. All shares of com...
Endocyte Announces FDA Acceptance of Radiographic Progression Free Sur...
Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS) Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval A positive assessment on either rPFS or OS is sufficient for full approval rPFS analysis expected late 2019, approximately one year ahead of final OS analysis Conference Call Today at 8:30 a.m. EDT WEST LAFAYETTE, Ind., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmac...
Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conferen...
Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference WEST LAFAYETTE, Ind., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, Sept. 5, at 3:00 p.m. EDT. A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at . The webcast...
UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018
UPDATE - Endocyte Announces Presentations at the CAR-TCR Summit 2018 WEST LAFAYETTE, Ind., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform will be presented at the CAR-TCR Summit 2018 being held from Sept. 4th - 7th, 2018 in Boston, MA. Key Presentations and Symposia:Chris Leamon, Ph.D., vice president of research at Endocyte, will lead a deep-dive workshop on t...
Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference
Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference WEST LAFAYETTE, Ind., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 14, at 3:40 p.m. EDT. A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at . The webcast will be arc...
Endocyte Provides Second Quarter 2018 Financial Results and Operationa...
Endocyte Provides Second Quarter 2018 Financial Results and Operational Update -Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035- -Investigational new drug (IND) filing for EC17/CAR T-cell therapy on track for fourth quarter 2018- -Conference call today at 8:30 a.m. EDT- WEST LAFAYETTE, Ind., July 31, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announce...
Endocyte Announces Second Quarter 2018 Financial Results and Operatio...
Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call WEST LAFAYETTE, Ind., July 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Tuesday, July 31st, at 8:30 a.m. EDT to discuss its second quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast of the call, which can be accessed in the Investors & News section ...
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-A...
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177 Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 WEST LAFAYETTE, Ind. and GARCHING, Germany, July 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical group of companies, announced today that ITM´s subsidiary, Isotope Technologies Garching GmbH (ITG), and Endocyte have signed a long-term global supply agreement for the highly purified, no-carrier-added Lutetiu...
Image Following Treatment with 177Lu-PSMA-617 Selected by Society of N...
Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year Image depicts PSMA PET scans of eight patients with exceptional responses from investigator-sponsored Phase 2 study WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of 177Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum Cancer Centre in Melbourne, Australia, was selec...
Endocyte to Join the Russell 3000® Index
Endocyte to Join the Russell 3000® Index WEST LAFAYETTE, Ind., June 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected for inclusion in the broad-market Russell 3000® Index following the Russell US Indices annual reconstitution, effective when the US markets open on Monday, June 25, 2018. Russell US Indices are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active ...
Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nu...
Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting Presentations highlight Endocyte’s alpha and beta-emitting radioligand therapies WEST LAFAYETTE, Ind., June 22, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple presentations related to Endocyte’s PSMA-617 radioligand therapy will be presented at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting (SNMMI) being held...
Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial...
Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer Additional data from phase 2 investigator-initiated trial of 177Lu-PSMA-617 presented at American Society of Clinical Oncology (ASCO) WEST LAFAYETTE, Ind., June 05, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the enrollment of the first patient in its global phase 3 VISION trial of 177Lu-PSMA-617 in prostate cancer by Dr. Luke Nordquist at Urology Cancer Cente...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.